TCM
MNPR icon

TCG Crossover Management’s Monopar Therapeutics MNPR Stock Holding History

TCG Crossover Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.24M Sell
132,103
-9,812
-7% -$593K 0.21% 42
2025
Q4 		$9.27M Sell
141,915
-11,085
-7% -$906K 0.31% 36
2025
Q3 		$12.5M Buy
+153,000
New +$6.84M 0.61% 31

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCG Crossover Management's MNPR Position: Q1 2026 in Review

TCG Crossover Management reduced its Monopar Therapeutics (MNPR) stake by 6.9% in Q1 2026, selling an estimated $593K and leaving 132,103 shares worth $7.24M. The position accounts for 0.21% of the portfolio, ranked #42.

TCG Crossover Management first reported a position in MNPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $12.5M in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • TCG Crossover Management held 132,103 shares of Monopar Therapeutics worth $7.24M as of Q1 2026.
  • TCG Crossover Management sold 9,812 Monopar Therapeutics shares in Q1 2026, an estimated $593K.
  • Monopar Therapeutics made up 0.21% of TCG Crossover Management's portfolio in Q1 2026, its #42 holding.
  • TCG Crossover Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • TCG Crossover Management's Monopar Therapeutics position peaked at $12.5M in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.